Clinical Trials
39 trialsA Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Astellas Pharma Inc
VIRO-25
Genelux Corporation
Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
ImmunityBio, Inc.
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Bristol-Myers Squibb
RASolute 303
Revolution Medicines, Inc.
ARC-8
Arcus Biosciences, Inc.
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
DualityBio Inc.
PRISM-1
Arcus Biosciences, Inc.
RASolute 302
Revolution Medicines, Inc.
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
RASolute 305
Revolution Medicines, Inc.
VELOCITY-Lung
Gilead Sciences
MTAPESTRY 103
Amgen
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Merck Sharp & Dohme LLC
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Merck Sharp & Dohme LLC
TroFuse-011
Merck Sharp & Dohme LLC
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Bristol-Myers Squibb
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Hutchmed
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Astellas Pharma Inc
INTerpath-13
Merck Sharp & Dohme LLC
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc.
MK-3475-01G
Merck Sharp & Dohme LLC
MK-2870-010
Merck Sharp & Dohme LLC
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
BioNTech SE
TeLuRide-008
Eikon Therapeutics
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
MedImmune LLC
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
GOBLET
Oncolytics Biotech
MountainTAP-29
Bristol-Myers Squibb
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
AstraZeneca
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Trishula Therapeutics, Inc.
NUMANTIA-2
Nelum Corp
MAGELLAN
AstraZeneca
EPIK-B3
Novartis
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.